AnHeart Says ROS1 Inhibitor Effective for NSCLC in Phase II Trial

AnHeart Therapeutics, a New York-Shanghai biopharma, reported its next-gen ROS1 inhibitor shrank tumors in 92% of treatment-naïve patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). The interim data was collected from a global pivotal Phase II trial of taletrectinib. Taletrectinib also showed intracranial activity in 62% of patients whose disease had spread to the brain. Taletrectinib is an oral, brain penetrant ROS1 inhibitor. Median progression-free survival has not been reached for TKI naïve patients. According to AnHeart, patients with ROS1 NSCLC do not respond well to available TKI drugs, creating an un-met need. More details.....

Share this with colleagues: